CD163 Antibody and Checkpoint Inhibitor Combinations for T Cell Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using immune checkpoint inhibitors and CD163 antibodies are limited by immunosuppression of T cells, which reduces their effectiveness in targeting cancer cells.
Innovation Solution
Administering a combination of an immunomodulatory CD163 antibody and an immune checkpoint inhibitor, such as a PD-1 or PD-L1 antagonist, to specifically bind to human CD163 on myeloid cells, thereby reducing immunosuppression and enhancing T cell activity and proliferation, leading to an increased immune response against cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint inhibitors and CD163 antibodies are administered alone, then they provide some therapeutic effect, but T cell immunosuppression reduces their effectiveness in targeting cancer cells
Solution Approach 1:
The patent combines immune checkpoint inhibitors with CD163-targeting antibodies into a single therapeutic regimen. This merging of two separate mechanisms (checkpoint inhibition and CD163 blockade) creates a synergistic effect that overcomes T cell immunosuppression more effectively than either agent alone, directly addressing the limitation of reduced therapeutic effectiveness
2Productivity
If combination therapy with immunomodulatory CD163 antibody and immune checkpoint inhibitor is administered, then T cell activity and proliferation increase, but treatment complexity increases
Solution Approach 1:
The patent merges multiple therapeutic agents into a coordinated combination regimen that can be administered together or in sequence. This approach achieves enhanced T cell proliferation and anti-tumor activity while managing treatment complexity through established administration protocols and scheduling
Data Source
AI summary
Provided herein are uses of antibodies that bind to CD163 expressed on a human myeloid cell in combination with checkpoint inhibitors. Among other things, these CD163 antibodies can be used with checkpoint inhibitors in methods of treatment of humans, such as methods of treating a cancer or methods of relieving T cell suppression.